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days at intensive care unit. The incremental cost per bed-day
saved was R$419,66. CONCLUSION: The NAGIS(c) model of
managed high cost patient, called Case Management Program is
cost-effective where the incremental cost per bed-day saved is
$419,66, and its return of investment is highly positive.
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OBJECTIVE: The purpose of this analysis was to develop a
method for identifying Medicare Part D members with cardio-
vascular disease using medication proxies. METHODS: A binary
matrix was created from cardiovascular medication prescription
claims for Medicare Part D MAPD and commercial members
from the ﬁrst quarter of 2007. The binary matrix was subjected
to factor/principal component analysis. The maximum valued
factor loading for each of the generated components were then
used to create a member/factor loading matrix. This matrix was
used to derive beta coefﬁcients, from logistic regression, to cal-
culate a member’s probability of having hypertension, CAD, or
CHF. RESULTS: One-hundred and twelve factors were produced
over 696,471 members prescribed cardiovascular medications.
Different probability thresholds were evaluated to determine the
sensitivity and speciﬁcity for the identiﬁcation method. The
threshold probabilities ran from >0.30 to >0.975. As the thresh-
old probabilities increased, sensitivity/speciﬁcity for hyperten-
sion, CAD, and CHF ran from 0.99/0.50–0.50/0.99, 0.61/0.91–
0.50/0.99, and 0.63/0.96–0.50/0.99, respectively. A similar result
was produced using maximum score coefﬁcients resulting from
the principal component analysis. CONCLUSION: Although
this approach to identifying members with medication proxies
appears to separate members with and without certain cardio-
vascular conditions, it tends to exclude members at the cost of
minimizing erroneously identiﬁed members.
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OBJECTIVE: Some contend that prescription copayment
increases reﬂect a disproportional shifting of costs to members
while others believe that copayments are simply keeping pace
with rising prescription costs. To better understand the drivers of
prescription cost sharing, this analysis examines recent trends
in member copayments relative to total prescription costs.
METHODS: The study is a retrospective descriptive analysis of
prescription claims data for a sample of commercially-insured
members enrolled with Express Scripts between 2002 and 2006.
Plan sponsors included in the analysis offered integrated prescrip-
tion coverage within an employer-based market (no Medicare or
Medicaid). For each year, the data represent prescription claim
activity for over 18 million members. Total per-prescription costs
were calculated as the sum of the discounted ingredient cost,
dispensing fee, administrative fees and any applicable tax divided
by the number of 30-day equivalent prescriptions. Average
member per-prescription cost was calculated as the total member
cost divided by the total number of 30-day equivalent prescrip-
tions. Costs were calculated separately for generics, preferred
brands and non-preferred brand-name prescriptions. RESULTS:
From 2002 to 2006 the average total per-prescription cost
increased $10.23 or 20.5% while the average member per pre-
scription copayment increased by $1.70 or 14.3%. The propor-
tion of total costs paid by members decreased from 24% in 2002
to 23% in 2006. Per-prescription member costs increased by
10% for generics, 25.7% for preferred brands and 58.6% for
non-preferred brands. CONCLUSION: These ﬁndings suggest
that plan sponsors are not shifting a greater proportion of costs
to members, nor is member cost share keeping pace with rising
prescription costs. Actual per-prescription member cost share
increased at a modest rate, inﬂuenced by increased generic use
which grew from 42% in 2002 to 58% in 2006.
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OBJECTIVE: The aim of this study was to evaluate trends in the
use of herbs and dietary supplements (HDS) in relation to pre-
scription drug (Rx) use, as well as their individual use, among US
adults from 1999–2004. METHODS: Data were abstracted from
the 1999–2000 and 2003–2004 cycles of the National Health
and Nutrition Examination Survey (NHANES). HDS included
herbs, vitamins, minerals, and other supplements. Trends in HDS
and/or Rx use were examined based on stratiﬁed characteristics
(i.e., sociodemographics, insurance coverage, health care visits
during the preceding year, chronic conditions). Sampling weights
were adjusted to allow for the pooling of data from multiple
waves. RESULTS: Overall, the proportion of HDS users
increased from 51.2% during 1999–2000 to 53.0% during
2003–2004, while that of Rx users increased from 49.9% to
55.6% over the same period. Between 1999 and 2004, the pro-
portion of HDS-only users decreased while the proportion of
people who only used Rx increased. The concomitant use of HDS
and Rx increased for most subgroups, except for those who had
an annual household income less than $14,999 or greater than
$65,000, and who had never have health care visits during the
preceding year. CONCLUSION: Trends suggest that concomi-
tant HDS and Rx use increased over the period of observation in
the general US population. Further research is needed to inves-
tigate the outcomes of concurrent HDS and Rx use.
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OBJECTIVE: Drug expenditures have been increasing much
faster than spending on other medical services and have become
burdensome for state Medicaid programs. This study was to
analyze the trends of Medicaid drug utilization and expenditures
across all major therapeutic classes and to identify their similari-
ties and differences. METHODS: Quarterly Medicaid reim-
bursed drug prescriptions and dollar amounts for each drug were
extracted from the national claims data from the Centers for
Medicare & Medicaid Services for 1991 through 2004. Expen-
ditures were aggregated across all drugs in 64 different therapeu-
tic classes, providing 64 different time series of length 56 quarters
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each. Principal components analysis (PCA) was then applied to
the data to identify major types of expenditure trends across all
the different therapeutic classes. RESULTS: In total, across all
drugs in the 64 therapeutic classes, Medicaid spending increased
from $4.6 billion with 231 million prescriptions in 1991 to $22.5
billion with 350 million prescriptions in 2004, representing total
Medicaid spending on outpatient drugs during the time period.
PCA revealed three principal components that accounted for 90
percent of total variation in Medicaid drug expenditure patterns.
The ﬁrst principal component (PC1), explaining 66 percent of the
variation, is an exponential-like upward trend; PC2, explaining
17% of the variation, represents an increasing-then-decreasing
expenditure pattern; and PC3, explaining 7% of the variation,
represents an up-and-down cyclical expenditure pattern. Thera-
peutic classes exhibiting high correlation (r > 0.9) with PC1
include corticoid steroids, anti-neoplastics, anti-seizure agents,
bone density regulators, anti-inﬂammatory agents, antiretroviral
agents, antipsychotics, antidepressants, oral diabetic agents, and
gastrointestinal agents. When PCA was applied to drug utiliza-
tion trends, the same principal components were discovered and
accounted for 92% of total variation in drug utilization patterns.
CONCLUSION: Most drug therapeutic classes exhibited
exponential-like upward expenditure trends, clearly contributing
to the overall rising expenditure burden for Medicaid.
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OBJECTIVE: To describe and characterize a group of private
insurance members taking multiple medications over a one-year
period. METHODS: Persons were selected for this polyphar-
macy analysis if they had at least ﬁve unique maintenance pre-
scriptions in their pharmacy claims records for the period of
January-March 2005, based on a customized list of chronic
medications. The full set of pharmacy and medical claims for
these members were evaluated for a 12-month period, October
2004 to September 2005. Standard descriptive statistics were
calculated to characterize the population. Logistic regression
models were used to assess the association of pharmacy claims
and “safety events” (i.e., emergency room visits (ER) and hospi-
talizations (H)). RESULTS: The ﬁnal analytic sample, having
both pharmacy and medical coverage for the period, consisted of
N = 14,890 members 19 years of age (66% female), from four
U.S. states. There were over 93,000 unique pharmacy claims
with a monthly average of 6.3 per member. Males (M) and
females (F) had similar averages (M = 6.2; F = 6.3), yet males
were more likely to have ER (12.1%M vs. 10.8%F, p = 0.022)
and H (8.3%M vs. 6.3%F, p < 0.0001). Unadjusted logistic
regressions estimated the effect of medication claims on ER and
H as OR = 1.14, p < 0.0001 and OR = 1.18, p < 0.0001, respec-
tively. This implies 14% and 18% higher odds of ER or H,
respectively, for every unit increase in monthly medications.
Adjusting for age and gender does not substantially affect these
results. CONCLUSION: Evaluating serious medical events in
sub-populations taking multiple prescription medications pro-
vides important information for health insurers trying to reduce
ER and hospitalizations. In a privately insured polypharmacy
sub-population, there was a strong association with these safety
events and increased average monthly pharmacy claims. Private
insurers should consider establishing managed care programs to
evaluate and improve the overall safety of their members taking
higher numbers of monthly medications.
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OBJECTIVE: The National Health Insurance (NHI) system in
Taiwan is characterized by 1) free choice of physicians and health
care facilities without formal referral; 2) generous drug beneﬁts;
and 3) low co-payments. The NHI beneﬁciaries thus exhibit
features of frequent attendances, frequent changes of physicians,
and a higher number of drug items in a prescription. It is inter-
esting to know how likely a doctor shopper is to be a patient of
polypharmacy. METHODS: The data sources came from the
historical claims datasets of 200,000-person cohort in 2005,
offered by the National Health Insurance Research Database in
Taiwan. The analysis was limited to the ambulatory records with
conditions of chronic diseases, represented by visits with more
than seven days of drug supply. For those people with at least one
visit for chronic diseases, the degree of correlation between the
total number of consulted facilities and the total number of
distinct prescribed drug items in all visits for chronic diseases in
2005 would be determined. RESULTS: Of the study cohort
56,956 people (30,070 females and 26,886 males; mean age
49.9  19.9 [SD] years) had at least one visit for chronic diseases
in 2005. On average, one of these people had paid 6.8  7.0
(max. 98) visits, consulted 1.5  0.9 (max. 32) facilities, and
received 7.3  7.3 (max. 93) distinct drug items for chronic
diseases in a year. The total number of consulted facilities for
chronic diseases in a year was strongly correlated with the total
number of distinct prescribed drug items in all visits for chronic
diseases in a year (Spearman’s rho 0.548, p < 0.001 [2-tailed]).
CONCLUSION: More visits for chronic diseases at different
facilities were related to more drugs prescribed. Besides the
patients’ reasons, the causes inherent in the health care system
deserve investigations.
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OBJECTIVE: Dosing and therapeutic range of digoxin has
recently changed based on results from clinical trials. We exam-
ined the epidemiology, mortality and length of stay (LOS) of
patients with serum digoxin level results during hospitalization.
METHODS: We retrospectively analyzed 4765 cases with serum
digoxin levels from 2 institutions that electronically provided
laboratory data from 2004–2006. Cases were stratiﬁed into the
groups based on maximum serum digoxin level; <1.0, 1.0–2.0,
2.1–2.4, and >2.4. The actual to predicted hospital mortality and
length of stay was compared across each strata with predicted
mortality and LOS determined by previously described admis-
sion based clinical models. RESULTS: Approximately 3 in 5
cases (57.8%) had a serum digoxin level higher than the recom-
mended range of <1.0. The crude mortality for cases with
digoxin levels <1.0 was 4.1% and 9.1% for those with digoxin
levels  1.0. After adjustment for severity of illness on admission
cases with a digoxin level  1.0 had a signiﬁcantly higher actual
to predicted mortality ratio (1.3 [CI = 1.1–1.4]) than cases <1.0
(0.8 [0.7–1.0]). While crude LOS was higher for serum digoxin
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